Jim Simons Ascendis Pharma A/S Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$69.96 - $97.84 $5.79 Million - $8.09 Million	82,699 New	82,699 $7.38 Million
Q3 2020 Nov 13, 2020	SELL	$134.29 - $154.32 $7.4 Million - $8.5 Million	-55,082 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $443,923 - $624,664	4,004 Added 7.84%	55,082 $8.15 Million
Q1 2020 May 14, 2020	BUY	$97.01 - $145.11 $2.06 Million - $3.08 Million	21,235 Added 71.16%	51,078 $5.75 Million
Q4 2019 Feb 13, 2020	SELL	$91.45 - $139.12 $4.09 Million - $6.23 Million	-44,756 Reduced 60.0%	29,843 $4.15 Million
Q3 2019 Nov 13, 2019	SELL	$95.8 - $118.9 $10.1 Million - $12.5 Million	-105,200 Reduced 58.51%	74,599 $7.19 Million
Q2 2019 Aug 12, 2019	BUY	$107.11 - $132.09 $9.75 Million - $12 Million	91,000 Added 102.48%	179,799 $20.7 Million
Q1 2019 May 14, 2019	BUY	$62.15 - $129.99 $5.52 Million - $11.5 Million	88,799 New	88,799 $10.5 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.